Evidence map›Paper›PMID 31949566›Full record

ArticleInternational journal of clinical and experimental pathology2018

CREB5 promotes cell proliferation and correlates with poor prognosis in hepatocellular carcinoma.

Jian Wu, Shu-Tong Wang, Zi-Jian Zhang, Qi Zhou, Bao-Gang Peng

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. MicroRNA-204/CREB5 axis regulates vasculogenic mimicry in breast cancer cells.Cancer biomarkers : section A of Disease markers · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jian WuDepartment of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong Province, PR China.
Shu-Tong WangDepartment of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong Province, PR China.
Zi-Jian ZhangDepartment of General Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University Shenzhen, Guangdong Province, PR China.
Qi ZhouDepartment of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong Province, PR China.
Bao-Gang PengDepartment of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong Province, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CAMP responsive element binding protein 5 (CREB5) has been reported to be overexpressed in several types of human cancers and has crucial roles in regulating cell growth, proliferation, differentiation, and the cell cycle. However, the expression and function of CREB5 in hepatocellular carcinoma (HCC) remains unclear. The purpose of this study was to investigate the role of CREB5 in HCC, and its prognostic significance. We measured the expression of CREB5 in 91 specimens of paraffin-embedded HCC tissue by immunohistochemistry and performed a clinicopathological analysis. Gain of function and loss of function assays were used to evaluate the effect of CREB5 on cell proliferation

Indexed as

CREB5HCCprognosisproliferation

Identifiers

PMID31949566
PMCPMC6962929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.